BioCentury | Nov 10, 2020
Product Development

Reata, Calliditas make good on renewed interest in kidney disease with Phase III successes

Two renal diseases are on track for their first approvals after a pair of Phase III studies hit primary endpoints, suggesting renewed interest in the therapeutic area is paying off for patients and investors....
BioCentury | Sep 25, 2020

Palladio seeks to position Orphan kidney therapy as safer alternative with $20 million series B

Palladio will use its $20 million series B round to determine for investors and potential partners where exactly its autosomal dominant polycystic kidney disease (ADPKD) therapy lixivaptan will fit on the market. The round was...
BioCentury | Jul 31, 2020
Product Development

U.K. locks down access to recombinant protein vaccine via GSK, Sanofi deal, its fourth for COVID-19

This story was updated to correct the nature of Imperial College's deal with the U.K. As the U.K. pushes to secure access to several mechanistically diverse vaccines, the country’s procurement deal with GSK and Sanofi...
BioCentury | Jun 12, 2020

Reata rebound

Shares of Reata Pharmaceuticals Inc. (NASDAQ:RETA) rose $36.76 (28%) to $167.68 on Thursday following a $350 million investment from Blackstone Life Sciences. The deal, which includes a $50 million equity investment and a $300 million...
BioCentury | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

One hundred days after taking the helm as CEO, Paul Hudson has outlined a plan to get Sanofi to 30% margins by 2022 that hinges largely on the success of Dupixent and five other priority...
BioCentury | Nov 13, 2019
Clinical News

Bardoxolone data set Reata up to advance second compound toward registration

Weeks after regaining rights to cardiorenal compounds from AbbVie, Reata has reported its second pivotal trial success of the quarter, paving the way for global marketing applications for its two most advanced compounds as it...
BioCentury | Oct 10, 2019
Company News

On eve of pivotal data, Reata pays AbbVie $330M to regain cardiorenal candidates

With AbbVie having turned away from cardiovascular and renal indications, Reata reacquired rights to bardoxolone and second-generation NRF2 activators from its long-standing partner for $330 million in cash ahead of upcoming pivotal readouts for two...
BioCentury | Oct 3, 2019
Product Development

Kidney is the new liver: why kidney indications are coming into sharp focus

Interest in kidney diseases is mounting among investors, biotechs and pharmas at a rate reminiscent of the liver disease explosion almost a decade ago. The momentum is driven by improvements at both ends of the...
BioCentury | Sep 11, 2019
Product Development

Pharmas’ challenge: learning from rare disease units while leaving them alone

How do you build a rare disease portfolio inside a pharma focused on large indications, and do right by both the new and the old? That’s a question faced by pharmas expanding from their traditional...
BioCentury | Aug 22, 2019
Financial News

Eyeing new endpoints, Versant-backed Chinook reels in $65M series A for kidney therapies

Increased momentum in the kidney disease space, sparked in part by an evolution in FDA's thinking about approvable endpoints, encouraged a VC syndicate to back newly launched Chinook with $65 million in series A funding....
Items per page:
1 - 10 of 125